Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. GPCR expression profile of primary cultured human pulmonary microvascular endothelial cells and normal human pulmonary fibroblasts.
  • Fig. S2. FACS gating strategy to isolate mouse pulmonary fibroblasts, epithelial cells, and endothelial cells from Col1a1-GFP transgenic mice.
  • Fig. S3. Expression of Drd1-4 in freshly isolated mouse lung fibroblasts, epithelial cells, and endothelial cells.
  • Fig. S4. DHX inhibits nuclear localization of YAP and TAZ.
  • Fig. S5. Representative YAP/TAZ localization in IPF-derived fibroblasts, alveolar epithelial cells, and pulmonary microvascular endothelial cells treated with DHX.
  • Fig. S6. Expression of additional YAP/TAZ target genes in fibroblasts, epithelial cells, and endothelial cells treated with D1 and EP2 receptor agonists.
  • Fig. S7. Prostaglandin E2 receptor expression in human lung fibroblasts, epithelial cells, and endothelial cells and loss of potency in IPF patient–derived lung fibroblasts.
  • Fig. S8. DHX activity is dependent on DRD1 receptor.
  • Fig. S9. DHX represses lung fibroblast proliferation without acute cytotoxicity.
  • Fig. S10. DHX reduces collagen I and fibronectin protein expression.
  • Fig. S11. DHX inhibits profibrotic gene expression and matrix deposition through inhibition of YAP/TAZ.
  • Fig. S12. DHX and YAP/TAZ siRNA modulate matrix cross-linking and degradation gene programs.
  • Fig. S13. DHX alone does not affect lung matrix content or profibrotic gene expression.
  • Fig. S14. Liver function tests in BDL experiments.
  • Fig. S15. Dopamine promotes antifibrotic effects.
  • Fig. S16. DDC transcripts inversely correlate with the stage of GAP function score, a clinically validated tool to predict 1-year mortality.
  • Fig. S17. DDC expression in subjects with alcoholic hepatitis.
  • Table S1. GPCR expression profiles from primary human lung fibroblasts, epithelial cells, endothelial cells, HSCs, and hepatocytes.
  • Table S2. Dopaminergic agonist library effects on YAP/TAZ localization.
  • Table S3. Dopaminergic agonist library effects on αSMA expression.
  • Table S4. Clinical and demographic characteristics of the Lung Genomics Research Consortium cohort.
  • Table S5. Polymerase chain reaction primers used in this study.
  • Legend for data file S1
  • References (97106)

[Download PDF]

Other Supplementary Material for this manuscript includes the following: